Eckert & Ziegler: Record Sales with Good Development of Earnings

Berlin, March 30, 2011. The Berlin company Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for isotope applications in medicine, science and industry, has once again been able to increase its sales and the result from ongoing business operations in 2010. The group sales proceeds thereby grew largely organically initially to EUR 111 million, an increase of about 10% compared to the already strong previous year in terms of growth (2009: EUR 101 million). The result after tax and minority interests rose by 26% from EUR 7.5 million to EUR 9.4 million, whereby in the previous year the special items increasing the profit for comparison purposes were eliminated.

The result per share was EUR 1.81 and is lower than the adjusted value from the previous year (EUR 1.97) because the number of shares rose more in the fiscal year with 37% than the adjusted result with 26%.

In terms of business volume the segment that has seen the absolutely strongest growth figures is again the segment of Isotope Products, in which the sales figures rose from EUR 46.3 million in the previous year to EUR 50.8 million in 2010. Of this increase EUR 0.8 million can be attributed to the baseline effect of a firm acquisition, the rest to an increased demand, in particular for products for nuclear medicine imaging. In contrast the largest relative growth was achieved with 16% increase to EUR 22.6 million by the segment Radiopharmaceuticals. Here it was the sales of therapeutic Yttrium-90 for cancer treatment as well as manufacturing machines for clinics in particular that grew noticeably. In the segment Radiation Therapy the sales with prostate carcinoma implants and tumor radiation equipment declined slightly; however, through the sale of plant items to Russia the segment was able to increase its sales by EUR 1.8 million to EUR 32.1 million in spite of this. The new segment of environmental services is still in the start-up phase and rose by 3% to EUR 5.6 million.

The board of directors and supervisory board will suggest an increase in the dividends from EUR 0.45 to 0.60 per share at the shareholders' meeting on 19th May 2011.

Sales of between EUR 110 and 120 million and a result after tax and minority interests of at least EUR 10 million are expected for the fiscal year 2011. By the end of 2014 the board of directors is expecting a profitable increase in sales to around EUR 200 million per year.

With around 550 employees the Eckert & Ziegler Group belongs to the largest providers of isotope components for radiotherapy and nuclear medicine worldwide.

The board of directors